Home/Pipeline/ZZ6398

ZZ6398

Schizophrenia

Phase 1/2Active

Key Facts

Indication
Schizophrenia
Phase
Phase 1/2
Status
Active
Company

About Zhongze Therapeutics

Clinical-stage biotech developing next-generation antipsychotics, with lead candidate ZZ6398 targeting schizophrenia and depression.

View full company profile

About Zhongze Therapeutics

Clinical-stage biotech developing next-generation antipsychotics, with lead candidate ZZ6398 targeting schizophrenia and depression.

View full company profile

Therapeutic Areas

Other Schizophrenia Drugs